ID   1359-mel
AC   CVCL_8041
SY   1359-MEL; 1359 mel; 1359; Mel-1359
DR   cancercelllines; CVCL_8041
DR   Cosmic; 2163791
DR   ESTDAB; ESTDAB-047
DR   Wikidata; Q54581654
RX   PubMed=9670966;
RX   PubMed=10048982;
RX   PubMed=10754339;
RX   PubMed=15592718;
RX   PubMed=23851445;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01:01; B*08:01,40:01; C*07:01:01,03:04; DPB1*04:01,01:01:01; DQB1*03:01:01,02:01; DRB1*03:01:01,04:01:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ESTDAB=ESTDAB-047
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,14
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 8
ST   FGA: 20
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M.C., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//